Methdilazine, an orally active (histamine antagonist) antibiotic, demonstrates the ability to inhibit various mycobacteria with minimum inhibitory concentration (MIC) values ranging from 5-15 μg/mL both in vitro and in vivo. This efficacy positions it as a valuable compound for infectious disease research [1] [2].